Cargando…

Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir

BACKGROUND: Study C210 was a Phase IIa, exploratory trial to assess the activity of telaprevir on hepatitis C virus (HCV) early viral kinetics in treatment-naïve patients infected with genotype 4 (G4) HCV. METHODS: Patients were randomized to receive peginterferon and ribavirin alone, telaprevir mon...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Meyer, Sandra, Ghys, Anne, Dierynck, Inge, Beumont, Maria, Luo, Donghan, Picchio, Gaston
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030523/ https://www.ncbi.nlm.nih.gov/pubmed/24886541 http://dx.doi.org/10.1186/1743-422X-11-93

Ejemplares similares

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

Modeling Viral Evolutionary Dynamics after Telaprevir-Based Treatment
por: Haseltine, Eric L., et al.
Publicado: (2014)

Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated -Interferon/Ribavirin/Telaprevir Triple Therapy
por: Pradat, Pierre, et al.
Publicado: (2015)

Telaprevir
Publicado: (2012)

Evaluation of Persistence of Resistant Variants with Ultra-Deep Pyrosequencing in Chronic Hepatitis C Patients Treated with Telaprevir
por: Thomas, Xiomara V., et al.
Publicado: (2012)

Rapid virological response of telaprevir and boceprevir in a Brazilian cohort of HCV genotype 1 patients: a multicenter longitudinal study
por: Borba, Helena HL, et al.
Publicado: (2017)

Safety, pharmacokinetics and resistant variants of telaprevir alone for 12 weeks in hepatitis C virus genotype 1b infection
por: Yamada, I, et al.
Publicado: (2012)

Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1 infection
por: Thorlund, Kristian, et al.
Publicado: (2012)

Efficacy and safety of telaprevir, a new protease inhibitor, for difficult-to-treat patients with genotype 1 chronic hepatitis C
por: Hayashi, N, et al.
Publicado: (2012)

Pre-existence and Persistence of Resistant Minority Hepatitis C Virus Variants in Genotype 1-Infected Patients Treated With Simeprevir/Peginterferon/Ribavirin
por: Fevery, Bart, et al.
Publicado: (2016)

Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
por: Brogan, Anita J., et al.
Publicado: (2014)

Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1b
por: Toyota, J, et al.
Publicado: (2013)

Hepatitis C in Brazil: lessons learned with boceprevir and telaprevir
por: Gomes, Lenyta Oliveira, et al.
Publicado: (2018)

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysis
por: Cooper, Curtis L, et al.
Publicado: (2012)

Efficacy and Tolerability of Telaprevir for Chronic Hepatitis Virus C Genotype 1 Infection: A Meta-Analysis
por: Kong, Yuan, et al.
Publicado: (2012)

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir
por: D’Ambrosio, Roberta, et al.
Publicado: (2012)

Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C
por: Karino, Y, et al.
Publicado: (2014)

Prediction of Sustained Virological Response to Telaprevir-Based Triple Therapy Using Viral Response within 2 Weeks
por: Tamai, Hideyuki, et al.
Publicado: (2014)

Telaprevir Experience From Turkey
por: Komur, Suheyla, et al.
Publicado: (2015)

Cutaneous Eruption due to Telaprevir
por: Falcão, Eduardo Mastrangelo Marinho, et al.
Publicado: (2015)

Telaprevir or boceprevir for hepatitis C treatment: a first survey on pharmacoutilization
por: Capuozzo, Maurizio, et al.
Publicado: (2013)

Treatment of genotype one hepatitis C virus (HCV) infection in HIV co-infected patients using telaprevir based regimen
por: Siraj, Dawd S., et al.
Publicado: (2014)

Comment to “Telaprevir Experience From Turkey”
por: Akar, Tarik, et al.
Publicado: (2015)

Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir
por: Johnson, Mark, et al.
Publicado: (2014)

Chronic Hepatitis C Therapy in Liver Cirrhosis Complicated by Telaprevir-Induced DRESS
por: Mousa, Omar Y. S., et al.
Publicado: (2014)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Predictors of Response to 24-Week Telaprevir-Based Triple Therapy for Treatment-Naïve Genotype 1b Chronic Hepatitis C Patients
por: Abe, Hiroshi, et al.
Publicado: (2014)

Treatment of hepatitis C genotype 1 patients with severe fibrosis or compensated cirrhosis: the telaprevir early access program in patients from Romania
por: Streinu-Cercel, Adrian, et al.
Publicado: (2013)

Telaprevir combination therapy in HCV/HIV co-infected patients (INSIGHT study): sustained virologic response at 12 weeks final analysis
por: Montes, Marisa, et al.
Publicado: (2014)

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C
por: Colombo, M, et al.
Publicado: (2014)

Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C
por: Kondo, C, et al.
Publicado: (2016)

Impact of Specialty Pharmacy on Telaprevir-Containing 3-Drug Hepatitis C Regimen Persistence
por: Henderson, Rochelle R., et al.
Publicado: (2014)

Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany
por: Stahmeyer, Jona T., et al.
Publicado: (2013)

Efficacy and safety of telaprevir- and simeprevir-based triple therapies for older patients with chronic hepatitis C
por: Yamagiwa, Satoshi, et al.
Publicado: (2017)

Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection
por: Bichoupan, Kian, et al.
Publicado: (2017)

Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
por: Coilly, Audrey, et al.
Publicado: (2015)

Management and outcomes of side effects with focus on anaemia in patients with hepatitis C genotype 1 infection: the telaprevir early access program in patients from Romania
por: Streinu-Cercel, Adrian, et al.
Publicado: (2013)

Genotyping and sero-virological characterization of hepatitis B virus (HBV) in blood donors, Southern Ethiopia
por: Ambachew, Henock, et al.
Publicado: (2018)

Boceprevir (BOC) and Telaprevir (TPV) therapeutic drug monitoring in HCV and HIV-HCV infected patients treated with triple therapy Ribavirine/Peg-interferon/Boceprevir or Telaprevir: impact of the antiretroviral (ARV) treatment
por: Chantry, AS, et al.
Publicado: (2014)

Telaprevir-Induced DRESS Syndrome Associated With Salmonella typhi
por: Akar, Tarık, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_naciuqumog2fma4cs6on1nlgnv